Alerts will be sent to your verified email
Verify EmailINDOCO
Indoco Remedies
|
Zota Health Care
|
Panacea Biotec
|
|
---|---|---|---|
Operational Metrics
|
|||
Pharmaceutical Sector
|
|||
Number of ANDA's Filed in USA
|
57.0 . | n/a | 6.0 . |
Number of ANDA's Approved By USFDA
|
29.0 . | n/a | n/a |
Domestic Sales Growth - YoY
|
4.0 % | n/a | n/a |
US DMF Filings
|
26.0 . | n/a | n/a |
Global DMFs filed
|
147.0 . | n/a | n/a |
R&D as a % of Total Sales
|
6.0 % | 0.09 % | 5.51 % |
Financials
|
|||
5 yr Average ROE
|
11.09 % | -1.91 % | 17.16 % |
5yr average Equity Multiplier
|
1.79 | 1.71 | 1.61 |
5yr Average Asset Turnover Ratio
|
0.92 | 0.99 | 0.4 |
5yr Avg Net Profit Margin
|
6.73 % | -0.52 % | 19.26 % |
Price to Book
|
2.71 | 13.1 | 3.03 |
P/E
|
0.0 | 0.0 | 0.0 |
5yr Avg Cash Conversion Cycle
|
53.79 Days | 38.95 Days | -102.87 Days |
Inventory Days
|
66.59 Days | 94.16 Days | 109.97 Days |
Days Receivable
|
76.04 Days | 55.69 Days | 37.7 Days |
Days Payable
|
121.65 Days | 89.31 Days | 294.14 Days |
5yr Average Interest Coverage Ratio
|
7.97 | 18.17 | 2.9 |
5yr Avg ROCE
|
15.12 % | 1.25 % | -1.68 % |
5yr Avg Operating Profit Margin
|
15.97 % | 5.05 % | -1.99 % |
5 yr average Debt to Equity
|
0.38 | 0.03 | 0.05 |
5yr CAGR Net Profit
|
32.49 % | n/a | -64.03 % |
5yr Average Return on Assets
|
6.31 % | -0.16 % | 6.95 % |
Shareholdings
|
|||
Promoter Holding
|
58.9 % | 59.72 % | 72.48 % |
Share Pledged by Promoters
|
0.0 | 0.26 % | 0.0 |
Change in Promoter Holding (3 Yrs)
|
0.21 % | -8.39 % | -1.11 % |
Change in Mutual Fund Holding (3 Yrs)
|
1.0 % | 0.03 % | 0.0 |
Indoco Remedies
|
Zota Health Care
|
Panacea Biotec
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Therapeutic Area Wise Break-Up - Domestic
|
Therapeutic Area Wise Break-Up - Domestic
|
-
|
Therapeutic Area Wise Break-Up - Domestic
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|